ScienceDex / Researcher record
Caggiano, Anthony O
- Cognition Therapeutics, Inc. (no department on record)
From the FY2021 NIH awards this investigator leads as contact PI. The department is the award's.
- Top 1% Funded
- Rising Star
- R01 Holder
NIH Funding · FY2021
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2014 | $476,872 | 1 | #16,020 |
| 2016 | $889,977 | 1 | #7,974 |
| 2019 | $3,300,642 | 1 | #1,330 |
| 2021 | $26,042,000 | 3 | #51 |
| 2022 | $12,398,697 | 2 | #175 |
| 2023 | $8,479,107 | 1 | #330 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20141 record
- FY20161 record
- FY20191 record
- FY2021 · selected3 records
- FY20222 records
- FY20231 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2014 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2021 award records by amount
NIH award records listing Caggiano, Anthony O as a PI. Multi-PI records show the full award amount for context.
- 3R01AG058660-03S1A1R01Contact PIA Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimerʼs Disease$13.6Maward amount
- 1R01AG071643-01R01Contact PIA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies$10.8Maward amount
- 1SB1AG073028-01A1SB1Contact PIHuman AME study of CT1812, a small molecule in phase 2 clinical trials for the treatment of Alzheimer's disease$1.6Maward amount
Award organization
Organizations that administered FY2021 awards listing Caggiano, Anthony O as a PI.
FY2021 award administered by Cognition Therapeutics, Inc. (PA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2014First NIH AwardCognition Therapeutics, Inc.
- 2016$500K Cumulative Funding
- 2016$1M Cumulative Funding
- 2016Entered Top 50% NationallyRanked #7974
- 2019$2M Cumulative Funding
- 2019Entered Top 25% NationallyRanked #1330
- 2019Entered Top 10% NationallyRanked #1330
- 2019R01 Grant Holder
- 2021$5M Cumulative Funding
- 2021$10M Cumulative Funding
- 2021$25M Cumulative Funding
- 2021Entered Top 5% NationallyRanked #51
- 2021Entered Top 1% NationallyRanked #51
- 2023$50M Cumulative Funding